Literature DB >> 22418739

Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy.

James J Dowling1, Sandrine Arbogast, Junguk Hur, Darcee D Nelson, Anna McEvoy, Trent Waugh, Isabelle Marty, Joel Lunardi, Susan V Brooks, John Y Kuwada, Ana Ferreiro.   

Abstract

The skeletal muscle ryanodine receptor is an essential component of the excitation-contraction coupling apparatus. Mutations in RYR1 are associated with several congenital myopathies (termed RYR1-related myopathies) that are the most common non-dystrophic muscle diseases of childhood. Currently, no treatments exist for these disorders. Although the primary pathogenic abnormality involves defective excitation-contraction coupling, other abnormalities likely play a role in disease pathogenesis. In an effort to discover novel pathogenic mechanisms, we analysed two complementary models of RYR1-related myopathies, the relatively relaxed zebrafish and cultured myotubes from patients with RYR1-related myopathies. Expression array analysis in the zebrafish disclosed significant abnormalities in pathways associated with cellular stress. Subsequent studies focused on oxidative stress in relatively relaxed zebrafish and RYR1-related myopathy myotubes and demonstrated increased oxidant activity, the presence of oxidative stress markers, excessive production of oxidants by mitochondria and diminished survival under oxidant conditions. Exposure to the antioxidant N-acetylcysteine reduced oxidative stress and improved survival in the RYR1-related myopathies human myotubes ex vivo and led to significant restoration of aspects of muscle function in the relatively relaxed zebrafish, thereby confirming its efficacy in vivo. We conclude that oxidative stress is an important pathophysiological mechanism in RYR1-related myopathies and that N-acetylcysteine is a successful treatment modality ex vivo and in a vertebrate disease model. We propose that N-acetylcysteine represents the first potential therapeutic strategy for these debilitating muscle diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418739      PMCID: PMC3326256          DOI: 10.1093/brain/aws036

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  41 in total

1.  Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion.

Authors:  Nigel F Clarke; Leigh B Waddell; Sandra T Cooper; Margaret Perry; Robert L L Smith; Andrew J Kornberg; Francesco Muntoni; Suzanne Lillis; Volker Straub; Kate Bushby; Michela Guglieri; Mary D King; Michael A Farrell; Isabelle Marty; Joel Lunardi; Nicole Monnier; Kathryn N North
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

2.  De novo RYR1 heterozygous mutation (I4898T) causing lethal core-rod myopathy in twins.

Authors:  Aurelio Hernandez-Lain; Isabelle Husson; Nicole Monnier; Caroline Farnoux; Guy Brochier; Emmanuelle Lacène; Maud Beuvin; Mait Viou; Linda Manéré; Kristl G Claeys; Michel Fardeau; Joël Lunardi; Thomas Voit; Norma Beatriz Romero
Journal:  Eur J Med Genet       Date:  2010-10-01       Impact factor: 2.708

3.  Basal bioenergetic abnormalities in skeletal muscle from ryanodine receptor malignant hyperthermia-susceptible R163C knock-in mice.

Authors:  Cecilia Giulivi; Catherine Ross-Inta; Alicja Omanska-Klusek; Eleonora Napoli; Danielle Sakaguchi; Genaro Barrientos; Paul D Allen; Isaac N Pessah
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 4.  2',7'-Dichlorodihydrofluorescein as a fluorescent probe for reactive oxygen species measurement: Forty years of application and controversy.

Authors:  Xiuping Chen; Zhangfeng Zhong; Zengtao Xu; Lidian Chen; Yitao Wang
Journal:  Free Radic Res       Date:  2010-06

5.  RYR1 mutations are a common cause of congenital myopathies with central nuclei.

Authors:  J M Wilmshurst; S Lillis; H Zhou; K Pillay; H Henderson; W Kress; C R Müller; A Ndondo; V Cloke; T Cullup; E Bertini; C Boennemann; V Straub; R Quinlivan; J J Dowling; S Al-Sarraj; S Treves; S Abbs; A Y Manzur; C A Sewry; F Muntoni; Heinz Jungbluth
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

6.  Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy.

Authors:  Carlo Viscomi; Alberto B Burlina; Imad Dweikat; Mario Savoiardo; Costanza Lamperti; Tatjana Hildebrandt; Valeria Tiranti; Massimo Zeviani
Journal:  Nat Med       Date:  2010-07-25       Impact factor: 53.440

7.  Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods.

Authors:  Elena Zvaritch; Natasha Kraeva; Eric Bombardier; Robert A McCloy; Frederic Depreux; Douglas Holmyard; Alexander Kraev; Christine E Seidman; J G Seidman; A Russell Tupling; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-03       Impact factor: 11.205

Review 8.  Selenoproteins and protection against oxidative stress: selenoprotein N as a novel player at the crossroads of redox signaling and calcium homeostasis.

Authors:  Sandrine Arbogast; Ana Ferreiro
Journal:  Antioxid Redox Signal       Date:  2010-04-01       Impact factor: 8.401

9.  First genomic rearrangement of the RYR1 gene associated with an atypical presentation of lethal neonatal hypotonia.

Authors:  Nicole Monnier; Annie Laquerrière; Stéphane Marret; Alice Goldenberg; Isabelle Marty; Yves Nivoche; Joël Lunardi
Journal:  Neuromuscul Disord       Date:  2009-09-05       Impact factor: 4.296

10.  Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment.

Authors:  Sandrine Arbogast; Maud Beuvin; Bodvaël Fraysse; Haïyan Zhou; Francesco Muntoni; Ana Ferreiro
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

View more
  53 in total

1.  Understanding Symptoms in RYR1-Related Myopathies: A Mixed-Methods Analysis Based on Participants' Experience.

Authors:  Carlos Capella-Peris; Mary M Cosgrove; Irene C Chrismer; M Sonia Razaqyar; Jeffrey S Elliott; Anna Kuo; Magalie Emile-Backer; Katherine G Meilleur
Journal:  Patient       Date:  2020-08       Impact factor: 3.883

2.  Analysis of embryonic and larval zebrafish skeletal myofibers from dissociated preparations.

Authors:  Eric J Horstick; Elizabeth M Gibbs; Xingli Li; Ann E Davidson; James J Dowling
Journal:  J Vis Exp       Date:  2013-11-13       Impact factor: 1.355

3.  Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.

Authors:  Trent A Waugh; Eric Horstick; Junguk Hur; Samuel W Jackson; Ann E Davidson; Xingli Li; James J Dowling
Journal:  Hum Mol Genet       Date:  2014-04-23       Impact factor: 6.150

Review 4.  Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies.

Authors:  Elizabeth M Gibbs; Eric J Horstick; James J Dowling
Journal:  FEBS J       Date:  2013-07-25       Impact factor: 5.542

5.  Mouse model of severe recessive RYR1-related myopathy.

Authors:  Stephanie Brennan; Maricela Garcia-Castañeda; Antonio Michelucci; Nesrin Sabha; Sundeep Malik; Linda Groom; Lan Wei LaPierre; James J Dowling; Robert T Dirksen
Journal:  Hum Mol Genet       Date:  2019-09-15       Impact factor: 6.150

6.  Bioenergetic defects in muscle fibers of RYR1 mutant knock-in mice associated with malignant hyperthermia.

Authors:  Leon Chang; Xiaochen Liu; Christine P Diggle; John P Boyle; Philip M Hopkins; Marie-Anne Shaw; Paul D Allen
Journal:  J Biol Chem       Date:  2020-08-21       Impact factor: 5.157

7.  Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.

Authors:  Sheila Riazi; Natalia Kraeva; Sheila M Muldoon; James Dowling; Clara Ho; Maria-Alexandra Petre; Jerome Parness; Robert T Dirksen; Henry Rosenberg
Journal:  Can J Anaesth       Date:  2014-09-05       Impact factor: 5.063

8.  A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Sissel Løseth; Nicol C Voermans; Torberg Torbergsen; Sue Lillis; Christoffer Jonsrud; Sigurd Lindal; Erik-Jan Kamsteeg; Martin Lammens; Marcus Broman; Gabriele Dekomien; Paul Maddison; Francesco Muntoni; Caroline Sewry; Aleksandar Radunovic; Marianne de Visser; Volker Straub; Baziel van Engelen; Heinz Jungbluth
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

Review 9.  Recent advances using zebrafish animal models for muscle disease drug discovery.

Authors:  Lisa Maves
Journal:  Expert Opin Drug Discov       Date:  2014-06-14       Impact factor: 6.098

Review 10.  Emerging applications for zebrafish as a model organism to study oxidative mechanisms and their roles in inflammation and vascular accumulation of oxidized lipids.

Authors:  Longhou Fang; Yury I Miller
Journal:  Free Radic Biol Med       Date:  2012-08-11       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.